Department of Molecular Neurology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nürnberg, Erlangen, Germany.
Institute of Biochemistry, Christian-Albrechts-University Kiel, Kiel, Germany.
Biochim Biophys Acta Mol Cell Res. 2022 Jul;1869(7):119243. doi: 10.1016/j.bbamcr.2022.119243. Epub 2022 Feb 23.
Lysosomes are ubiquitous organelles with a fundamental role in maintaining cellular homeostasis by mediating degradation and recycling processes. Cathepsins are the most abundant lysosomal hydrolyses and are responsible for the bulk degradation of various substrates. A correct autophagic function is essential for neuronal survival, as most neurons are post-mitotic and thus susceptible to accumulate cellular components. Increasing evidence suggests a crucial role of the lysosome in neurodegeneration as a key regulator of aggregation-prone and disease-associated proteins, such as α-synuclein, β-amyloid and huntingtin. Particularly, alterations in lysosomal cathepsins CTSD, CTSB and CTSL can contribute to the pathogenesis of neurodegenerative diseases as seen for neuronal ceroid lipofuscinosis, synucleinopathies (Parkinson's disease, Dementia with Lewy Body and Multiple System Atrophy) as well as Alzheimer's and Huntington's disease. In this review, we provide an overview of recent evidence implicating CTSD, CTSB and CTSL in neurodegeneration, with a special focus on the role of these enzymes in α-synuclein metabolism. In addition, we summarize the potential role of lysosomal cathepsins as clinical biomarkers in neurodegenerative diseases and discuss potential therapeutic approaches by targeting lysosomal function.
溶酶体是普遍存在的细胞器,通过介导降解和回收过程,在维持细胞内稳态方面起着至关重要的作用。组织蛋白酶是最丰富的溶酶体水解酶,负责各种底物的大量降解。正确的自噬功能对于神经元的存活至关重要,因为大多数神经元是有丝分裂后细胞,因此容易积累细胞成分。越来越多的证据表明溶酶体在神经退行性变中起着关键作用,是聚集倾向和与疾病相关的蛋白质(如α-突触核蛋白、β-淀粉样蛋白和亨廷顿蛋白)的关键调节剂。特别是溶酶体组织蛋白酶 CTSD、CTSB 和 CTSL 的改变可能导致神经退行性疾病的发病机制,如神经元蜡样脂褐质沉积症、突触核蛋白病(帕金森病、路易体痴呆和多系统萎缩)以及阿尔茨海默病和亨廷顿病。在这篇综述中,我们概述了最近的证据,表明 CTSD、CTSB 和 CTSL 与神经退行性变有关,特别关注这些酶在α-突触核蛋白代谢中的作用。此外,我们总结了溶酶体组织蛋白酶作为神经退行性疾病临床生物标志物的潜在作用,并讨论了通过靶向溶酶体功能的潜在治疗方法。